Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure (PARADIGM-HF)
Source: View publication →
In patients with heart failure with reduced ejection fraction, combined angiotensin-receptor and neprilysin inhibition with sacubitril/valsartan significantly reduced the risks of cardiovascular death and heart failure hospitalization compared to the gold-standard ACE inhibitor enalapril.
Key Findings
Study Design
Study Limitations
Clinical Significance
PARADIGM-HF definitively established sacubitril/valsartan as a foundational therapy for HFrEF, proving it superior to the decades-old gold-standard ACE inhibitor, enalapril. The striking 20% relative risk reduction in cardiovascular mortality and heart failure hospitalizations led major international cardiological societies to rapidly update their guidelines, recommending the replacement of an ACE inhibitor or ARB with an Angiotensin Receptor-Neprilysin Inhibitor (ARNI) in symptomatic HFrEF patients. The trial successfully ushered in the modern era of concurrent neurohormonal inhibition and enhancement of the endogenous natriuretic peptide system.
Historical Context
For over 20 years following the landmark CONSENSUS (1987) and SOLVD (1991) trials, ACE inhibitors remained the undisputed cornerstone of medical therapy for treating heart failure with reduced ejection fraction (HFrEF). Previous attempts to combine RAAS inhibition with neprilysin inhibition (which prevents the breakdown of beneficial vasoactive natriuretic peptides) utilized combined ACE/neprilysin inhibitors such as omapatrilat. However, these failed due to synergistic bradykinin accumulation causing unacceptable and life-threatening rates of angioedema. The advent of LCZ696 (sacubitril/valsartan) bypassed this fatal flaw by combining a neprilysin inhibitor with an angiotensin-receptor blocker (ARB) instead of an ACE inhibitor. PARADIGM-HF was a watershed moment in cardiovascular medicine as the first trial to demonstrate a mortality benefit definitively superior to an ACE inhibitor, triggering a paradigm shift in HFrEF management.
Guided Discussion
High-yield insights from every perspective
Why is the neprilysin inhibitor sacubitril combined with an angiotensin receptor blocker (valsartan) rather than an ACE inhibitor like enalapril?
Key Response
Neprilysin degrades several vasoactive peptides, including bradykinin. ACE also degrades bradykinin. Combining a neprilysin inhibitor with an ACE inhibitor simultaneously blocks two major breakdown pathways for bradykinin, leading to unacceptably high rates of life-threatening angioedema (as historically seen with the dual-inhibitor omapatrilat). Thus, an ARB is used to safely achieve RAAS blockade without synergistically elevating bradykinin levels.
A patient with HFrEF currently on lisinopril 20mg daily is being transitioned to sacubitril/valsartan. What specific transition protocol must be followed in clinical practice and why?
Key Response
A strict 36-hour washout period between the last dose of an ACE inhibitor and the first dose of sacubitril/valsartan is required. This mandatory gap ensures that ACE activity has sufficiently recovered before neprilysin inhibition begins, significantly mitigating the overlapping inhibition of bradykinin degradation and preventing severe angioedema.
Following the initiation of sacubitril/valsartan, how should a clinician interpret changes in the patient's natriuretic peptide levels (BNP vs. NT-proBNP) to accurately monitor heart failure trajectory?
Key Response
Sacubitril inhibits neprilysin, an enzyme that directly degrades BNP. Therefore, BNP levels will artificially rise due to the medication and no longer accurately reflect a reduction in ventricular wall stress. Conversely, NT-proBNP is not a substrate for neprilysin. To assess physiological response and HF progression, clinicians must exclusively monitor NT-proBNP, which should appropriately decrease as the patient's hemodynamics improve on the ARNI.
Given the profound mortality benefit shown in PARADIGM-HF, how do you weigh the upfront cost, administrative burden, and risk of initial symptomatic hypotension when deciding whether to switch a clinically 'stable' HFrEF patient optimized on an ACE inhibitor to an ARNI?
Key Response
PARADIGM-HF demonstrated a significant 20 percent relative risk reduction in CV mortality even in supposedly 'stable' HFrEF patients. The key teaching point is that 'stable heart failure' is a misnomer; these patients retain a high baseline risk of sudden death and decompensation. With an impressive NNT of 21 for the primary outcome, the overwhelming evidence dictates that the switch is highly beneficial and practice-changing, meaning inertia to maintain the status quo in 'stable' patients deprives them of a major survival advantage.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
PARADIGM-HF utilized a sequential, single-blind active run-in period (first enalapril, then sacubitril/valsartan) before randomization. How does this specific study design choice impact the trial's internal validity versus its external generalizability?
Key Response
An active run-in period ensures only patients who can tolerate target doses of both drugs without severe adverse events are randomized. While this maximizes the statistical power and internal validity to detect long-term efficacy by minimizing non-adherence and dropouts, it significantly compromises external validity (generalizability). The real-world incidence of early adverse events like hypotension, hyperkalemia, or renal dysfunction during initiation will inevitably be higher than the rates reported in the post-randomization phase of the trial.
A major methodological critique during peer review was the selection and dosing of the active comparator. Does comparing sacubitril/valsartan 97/103 mg BID to enalapril 10 mg BID represent a scientifically rigorous evaluation of maximal RAAS blockade?
Key Response
From an editorial perspective, this is a critical threat to validity. Critics argue that while enalapril 10 mg BID was the target dose in the SOLVD trial, it may not represent the maximum tolerated RAAS inhibition achievable with modern agents like high-dose lisinopril or losartan. The reviewer must question whether the experimental arm succeeded strictly because the novel dual-mechanism is inherently superior, or simply because it provided a more potent total systemic blockade than the specific enalapril dose used.
Based on the outcomes of PARADIGM-HF, how should guidelines classify the recommendation to replace an ACEi or ARB with an ARNI in symptomatic HFrEF patients, and how does this update previous RAAS inhibition paradigms?
Key Response
In response to PARADIGM-HF, the ACC/AHA/HFSA guidelines issued a Class I recommendation (Level of Evidence: B-R) stating that for patients with chronic symptomatic HFrEF (NYHA class II or III) who tolerate an ACEi or ARB, replacement with an ARNI is recommended to further reduce morbidity and mortality. This marked a historic paradigm shift, elevating ARNI therapy above the decades-old gold standard of ACE inhibitors as the preferred foundational therapy for HFrEF.
Clinical Landscape
Noteworthy Related Trials
SOLVD-Treatment
Tested
Enalapril
Population
Patients with chronic heart failure and LVEF <= 35%
Comparator
Placebo
Endpoint
All-cause mortality
PARAGON-HF
Tested
Sacubitril/Valsartan
Population
Patients with heart failure and LVEF >= 45% (HFpEF)
Comparator
Valsartan
Endpoint
Composite of total hospitalizations for heart failure and cardiovascular death
DAPA-HF
Tested
Dapagliflozin 10mg daily
Population
Patients with heart failure and LVEF <= 40% (HFrEF)
Comparator
Placebo
Endpoint
Composite of worsening heart failure or cardiovascular death
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis